THE MODEL – TREATMENT OF MYOCARDIAL ISCHEMIA WITH S. ELONGATUS

A phosphorescent probe is used to determine oxygen tension at various points after an ischemic attack. Using this probe allows direct measurement of tissue oxygenation, while avoiding off-target scatter from blood in the ventricles.


Does the introduction of the bacteria into the human system elicit any immune response?

The effect of this on the immune system has been studied by Cohen et al (2017). According to the report by the researchers, there is no obvious inflammatory response to the therapy. A report by the researchers showed that “after intravenous delivery of 5 x 108 S. elongatus cells, blood cultures remained negative and did not show any signs of infection for the duration of 1-week observation period.” It is likely that the S. elongatus strain does not persist for long in the tissues, as most of the injected cells get cleared within 24 hours.


What is the market value for this model?

Based on the prevailing cost of heart disease to the global economy, and the “not-so-effective” treatment model, it is estimated that this model (the S. elongatus – based therapy) may have a god market value. Studies have shown that within 2 decades, the number of Americans with cardiovascular diseases will rise to about 131.2 million, making up 45 percent of the total population of the US. The cost is expected to reach $1.1 trillion.


Bio Tech RSS News Feed

[Valid RSS]
powered by Surfing Waves